News & Updates

Treatment with zuranolone 50 mg/day in adults with major depressive disorder (MDD) results in greater improvements in depressive symptoms at day 15, demonstrating a rapid time to effect (day 3), and is generally well tolerated, with no new safety concerns compared with lower dosages, reports a study.

Use of zuranolone significantly improves depressive symptoms, with no serious side effects, in women with severe postpartum depression (PPD), a common perinatal complication with adverse maternal and infant outcomes, results of a phase III trial have shown.

Early adolescents with higher vitamin D levels at baseline appear to be at lower risk of depression, a study has found.